Literature DB >> 15357216

Macrophage specific drug delivery in experimental leishmaniasis.

Mukul Kumar Basu1, Sanchaita Lala.   

Abstract

Macrophage-specific delivery systems are the subject of much interest nowadays, because of the fact that macrophages act as host cells for many parasites and bacteria, which give rise to outbreak of so many deadly diseases(eg. leishmaniasis, tuberculosis etc.) in humans. To combat these deadly diseases initially macrophage specific liposomal delivery system were thought of and tested in vivo against experimental leishmaniasis in hamsters using a series of indigenous or synthetic antileishmanial compounds and the results were critically discussed. In vitro testing was also done against macrophages infected with Leishmania donovani, the causative agent for visceral leishmaniasis. The common problem of liposome therapy being their larger size, stability and storage, non-ionic surfactant vesicles, niosomes were prepared, for their different drug distribution and release characteristics compared to liposomes. When tested in vivo, the retention capacity of niosomes was found to be higher than that of liposomes due to the absence of lipid molecules and their smaller size. Thus the therapeutic efficacy of certain antileishmanial compounds was found to be better than that in the liposomal form. The niosomes, being cheaper, less toxic, biodegradable and non-immunogenic, were considered for sometime as suitable alternatives to liposomes as drug carriers. Besides the advent of other classical drugs carriers(e.g. neoglycoproteins), the biggest challenge came from polymeric delivery vehicles, specially the polymeric nanoparticles which were made of cost effective biodegradable polymers and different natural polymers. Because of very small size and highly stable nature, use of nanoparticles as effective drug carriers has been explored in experimental leishmaniasis using a series of antileishmanial compounds, both of indigenous and synthetic origin. The feasibility of application in vivo, when tested for biological as well as for other physicochemical parameters, the polymeric nanoparticles have turned out to be the best and thus may be projected for effective use in the clinics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15357216     DOI: 10.2174/1566524043360186

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  17 in total

1.  In vitro evaluation of the effectiveness and cytotoxicity of meglumine antimoniate microspheres produced by spray drying against Leishmania infantum.

Authors:  G Pujals; J M Suñé-Negre; P Pérez; E García; M Portus; J R Tico; M Miñarro; J Carrió
Journal:  Parasitol Res       Date:  2008-02-17       Impact factor: 2.289

Review 2.  Bioavailability of phytochemicals and its enhancement by drug delivery systems.

Authors:  Farrukh Aqil; Radha Munagala; Jeyaprakash Jeyabalan; Manicka V Vadhanam
Journal:  Cancer Lett       Date:  2013-02-19       Impact factor: 8.679

3.  Nanodisk-associated amphotericin B clears Leishmania major cutaneous infection in susceptible BALB/c mice.

Authors:  Keith G Nelson; Jeanette V Bishop; Robert O Ryan; Richard Titus
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

4.  Advances in Integrative Nanomedicine for Improving Infectious Disease Treatment in Public Health.

Authors:  Iris R Bell; Gary E Schwartz; Nancy N Boyer; Mary Koithan; Audrey J Brooks
Journal:  Eur J Integr Med       Date:  2013-04-01       Impact factor: 1.314

5.  In vitro and in vivo antileishmanial efficacy of nitazoxanide against Leishmania donovani.

Authors:  Ruiyan Zhang; Liming Shang; Hongtao Jin; Cuiping Ma; Yongkui Wu; Quan Liu; Zhiping Xia; Feng Wei; Xing-Quan Zhu; Hongwei Gao
Journal:  Parasitol Res       Date:  2010-05-22       Impact factor: 2.289

6.  Nano to micro delivery systems: targeting angiogenesis in brain tumors.

Authors:  Ariel Gilert; Marcelle Machluf
Journal:  J Angiogenes Res       Date:  2010-10-08

7.  Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS.

Authors:  Huanyu Dou; Cassi B Grotepas; JoEllyn M McMillan; Christopher J Destache; Mahesh Chaubal; Jane Werling; James Kipp; Barrett Rabinow; Howard E Gendelman
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

8.  Sequential exposure to carbon nanotubes and bacteria enhances pulmonary inflammation and infectivity.

Authors:  Anna A Shvedova; James P Fabisiak; Elena R Kisin; Ashley R Murray; Jenny R Roberts; Yulia Y Tyurina; James M Antonini; Wei Hong Feng; Choudari Kommineni; Jeffrey Reynolds; Aaron Barchowsky; Vince Castranova; Valerian E Kagan
Journal:  Am J Respir Cell Mol Biol       Date:  2007-12-20       Impact factor: 6.914

9.  Preparation, characterization and evaluation of targeting potential of amphotericin B-loaded engineered PLGA nanoparticles.

Authors:  Manoj Nahar; Narendra K Jain
Journal:  Pharm Res       Date:  2009-10-20       Impact factor: 4.200

10.  Development of optical probes for in vivo imaging of polarized macrophages during foreign body reactions.

Authors:  David W Baker; Jun Zhou; Yi-Ting Tsai; Kaitlen M Patty; Hong Weng; Ewin N Tang; Ashwin Nair; Wen-Jing Hu; Liping Tang
Journal:  Acta Biomater       Date:  2014-04-13       Impact factor: 8.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.